The global Allogeneic Stem Cell Transplantation Market is estimated to be valued at US$ 3.9 Billion In 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 - 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Allogeneic stem cell transplantation involves transplanting stem cells from a donor into a patient. It is used to treat a variety of malignant and non-malignant disorders such as leukemia, lymphoma, multiple myeloma, genetic disorders, and more. The transplanted donor cells help replace damaged or destroyed bone marrow in the patient. It offers curative treatment for various life-threatening diseases and provides an opportunity for long-term survival.
Market key trends:
One of the key trends in the allogeneic stem cell transplantation market is the increasing number of clinical trials evaluating novel conditioning regimens and emerging alternative stem cell sources. Several studies are evaluating the use of reduced-intensity conditioning regimens which are less toxic than traditional myeloablative regimens. This is expected to increase the eligibility of patients for stem cell transplants. Additionally, alternative sources of stem cells such as cord blood and mesenchymal stem cells are being evaluated which can reduce the risks associated with traditional bone marrow transplantation and increase graft availability.
Segment Analysis
The global Allogeneic Stem Cell Transplantation Market is dominated by the hematopoietic stem cell transplantation segment, which accounted for around 70% of the market share in 2023. This is attributed to the significant usage of hematopoietic stem cells from blood, bone marrow, or umbilical cord blood to treat numerous blood cancers and disorders like leukemia and lymphoma. Another major sub-segment is mesenchymal stem cell transplantation that holds around 25% share. Mesenchymal stem cells are multipotent stromal cells that can differentiate into a variety of cell types and thus used to treat numerous conditions like graft-versus-host disease and musculoskeletal disorders.
Key Takeaways
The global allogeneic stem cell transplantation market size was valued at US$ 3.9 Billion In 2023. It is expected to witness high growth, exhibiting a CAGR of 7.9% over the forecast period, due to the increasing prevalence of blood cancers and disorders along with rising adoption of regenerative medicine therapies.
Regional analysis
The US dominated the market with around 40% share in 2023 due to favorable reimbursement policies and advanced healthcare infrastructure facilitating higher allogeneic stem cell transplant procedures in the country. The Asia Pacific region is expected to be the fastest-growing market during the forecast period owing to the improving healthcare outcomes, rising medical tourism, and increasing investment by key industry players in developing markets of China, India, and South Korea.
Key players
Key players operating in the allogeneic stem cell transplantation market are Celgene Corporation, Mesoblast Ltd., Pluristem Therapeutics Inc., MEDIPOST Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Cellular Biomedicine Group, Inc., Biosolution Co., Ltd., StemCell Technologies Inc., Caladrius Biosciences, Inc., TiGenix N.V., ViaCord, Vericel Corporation, Regen Biopharma Inc., Gamida Cell Ltd., Histogenics Corporation, BrainStorm Cell Therapeutics Inc., Lineage Cell Therapeutics, Inc. The major players are focusing on expanding their presence and capabilities in stem cell transplantation through collaborations and acquisitions.
Read More : https://www.rapidwebwire.com/allogeneic-stem-cell-transplantation-market-forecast-demand-analysis/
Comments
0 comment